Navigation Links
Gene Signal presents data at ARVO 2012 showing topical aganirsen is active in retinal disease
Date:5/8/2012

Fort Lauderdale, FL, USA and Lausanne, Switzerland, May 8, 2012 Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced that positive data from a study of aganirsen (GS-101, eye drops) in a nonhuman primate model of choroidal neovascularization has been presented at the 2012 ARVO Annual Meeting in Fort Lauderdale, Florida. Topical administration of aganirsen was found to inhibit neovascular growth and leakage in this model and strongly suggests a role for the drug candidate in human retinal neovascular diseases such as wet age-related macular degeneration (AMD) and ischemic retinopathy. Gene Signal's aganirsen is an antisense oligonucleotide that is expected to complete a phase III trial for the treatment of progressive neovascularisation in the cornea in 2012. Clinical studies in retinal diseases are schedule to begin during the second quarter 2012.

"This study demonstrates the ability of aganirsen to address neovascularization formation in the retina by inhibiting the expression of the angiogenic protein IRS-1. Importantly, this is achieved without affecting normal vascularisation," noted Dr. Matthew Lawrence of RxGen, Inc, who presented the data. "With the demand for new, effective antiangiogenic agents that are easier to use in the treatment of several eye diseases growing, we believe these data strongly support a role for aganirsen."

Aganirsen blocks pathological neovascularization by inhibiting IRS-1. Clinical studies to date have shown that aganirsen is able to safely and effectively inhibit the development of progressive corneal neovascularization secondary to infectious keratitis or chemical burns both of which could lead to corneal graft replacement.

"A topical agent for neovascular disease would revolutionize treatment. There is a huge unmet need for many opthalmological diseases including AMD, ischemic retinopathy and certain forms of glucoma," noted Eric Viaud, CEO of Gene Signal. "To confirm the many advantages that topical aganirsen could offer over currently available drugs, we intend to begin Phase II clinical evaluation in the next few months. We also acknowledge that a group of world leading experts have agreed to discuss the future development of aganirsen during the current ARVO conference. Their insight is invaluable and gratefully accepted by our team."

Study Details

Aganirsen (topical emulsion) was applied daily in non-human primates following laser induced choroidal neovascularisation (CNV), a model of wet age-related macular degeneration (AMD). Retinal aganirsen concentrations were assessed in monkeys following topical delivery (21.5, 43 or 86 g).

Aganirsen was found to inhibit dose-dependently neovascular lesion development, with the incidence of high-grade CNV lesions (grade IV, as measured by fluorescein signal intensity) decreasing from 20.5% in vehicle-treated animals to 1.7% (p<0.05) in animals treated with the highest dose of Aganirsen (86 g/day). The size of neovascularization complexes was also significantly lower in eyes receiving high dose and low dose aganirsen (p<0.0001) compared with vehicle-treated eyes.


'/>"/>

Contact: Mike Sinclair
msinclair@halsin.com
44-207-318-2955
Halsin Partners
Source:Eurekalert

Related medicine news :

1. Gatekeeper of brain steroid signals boosts emotional resilience to stress
2. Lightheadedness Upon Standing Could Signal Heart Risk
3. Kids Penicillin Allergy May Not Signal Other Drug Reactions
4. Cell signaling discovery provides new hope for blood disorders
5. Plant flavonoid luteolin blocks cell signaling pathways in colon cancer cells
6. Cell signaling key to stopping growth and migration of brain cancer cells
7. Impaired quality of life: A warning signal after oesophageal cancer surgery
8. Changes in Cerebrospinal Fluid May Signal Early Alzheimers
9. Thinner Brains Could Signal Alzheimers, Study Suggests
10. Holiday Blues May Signal Depression
11. Jump in Resting Heart Rate Might Signal Higher Death Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not ... the industry, according to the recent NEJM Catalyst Insights Report on the New ... NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, and ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume 2 features ... ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. Great for ... and choose from hand-crafted trend-setting designs with smooth animations that will add stylistic ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance ... change designed to further positively impact the health and wellness of our community ... considered it our duty to seriously consider releasing our assets beyond our 5% ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering ... Francis' goals for each and every seminar, session and class she offers. ... five different brainwave tools which help energize creativity, focus mental functions, enhance athletic ...
(Date:2/17/2017)... WASHINGTON (PRWEB) , ... February 17, 2017 , ... ... communities by fall 2017 season , Trinity Health and the U.S. Soccer Foundation ... for Success program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... DUBLIN , Feb. 17, 2017 ... ("Theravance Biopharma" or the "Company") today announced the ... novel, potent, and orally administered pan-Janus kinase (JAK) ... 12 th Congress of the European Crohn,s ... the Company reported further data from its completed ...
(Date:2/17/2017)... Research and Markets has announced the addition of the "Drug-Eluting ... ... for the US, Canada , Japan ... Latin America , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... LOUIS , Feb. 17, 2017   FormFast ... has announced a new partnership with Engage , ... the United States . FormFast will serve as ... of Engage,s implementations with MEDITECH .  ... provides essential functionality to complement and enhance the electronic ...
Breaking Medicine Technology: